DRKS00031054尚未招募不适用
se of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) patients in Germany – A retrospective evaluation in German centers for NET - LUNET-2
ovartis Radiopharmaceuticals GmbH0 个研究点目标入组 100 人开始时间: 2023年1月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Confirmed diagnosis of GEP-NET (any localization of the primary tumour including CUP2, any Grade)
- •First cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01st July 2020 and 30th June 2021
排除标准
- •Combination of PRRT with chemotherapy
- •Combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).
研究者
相似试验
进行中（未招募）
不适用
Peptide Receptor Radionuclide Therapy (PRRT) in advanced gastro-entero-pancreatic Neuroendocrine TumorsAdvanced gastro-entero-pancreatic Neuroendocrine Tumors, FDG-PET negative patientsMedDRA version: 16.0Level: HLGTClassification code 10014713Term: Endocrine neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003165-34-ITIRCCS-IRST of Meldola
进行中（未招募）
1 期
uclear Medicine therapy using synthetic somatostatin analogues that are radiolabelled with high-energy beta(-) emitting isotopes, for the treatment of tumors overexpressing somatostatin specific receptors (on the surface of the cell membrane) enable to bind and internalize the radiolabelled analogues mentioned aboveEUCTR2016-005129-35-ITAZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA250
已完成
不适用
Peptide receptor radionuclide therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) - Evaluation of treatment response and hemato- and nephrotoxicityGastroenteropancreatic neuroendocrine Tumors.C15-C26Malignant neoplasms of digestive organsDRKS00008976niversitätsklinikum Freiburg63
终止
1 期
Peptide Receptor Radionuclide Therapy administered to Participants withMeningioma with 67Cu-SARTATE™Cancer - BrainCancer - Head and neckCancer - Other cancer typesMeningiomaACTRN12618000309280Clarity Pharmaceuticals Ltd.5
进行中（未招募）
1 期
Peptide receptor radionuclide therapy in tumors with high expression of somatostatine receptors.EUCTR2015-005546-63-ITAZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA120